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Abstract
Germline mutations of FH, the gene that encodes for the tricarboxylic acid TCA (TCA) cycle enzyme fumarate hydratase, are
associated with an inherited form of cancer referred to as Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC).
Individuals with HLRCC are predisposed to the development of highly malignant and lethal renal cell carcinoma (RCC). The
mechanisms of tumorigenesis proposed have largely focused on the biochemical consequences of loss of FH enzymatic
activity. While loss of the tumor suppressor gene von Hippel Lindau (VHL) is thought to be an initiating event for the majority
of RCCs, a role for FH in sporadic renal cancer has not been explored. Here we report that FH mRNA and protein expression
are reduced in clear cell renal cancer, the most common histologic variant of kidney cancer. Moreover, we demonstrate that
reduced FH leads to the accumulation of hypoxia inducible factor- 2a (HIF-2a), a transcription factor known to promote
renal carcinogenesis. Finally, we demonstrate that overexpression of FH in renal cancer cells inhibits cellular migration and
invasion. These data provide novel insights into the tumor suppressor functions of FH in sporadic kidney cancer.
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Introduction
In 2010, over 57,000 men and women will be diagnosed with
renal cell carcinoma (RCC) and 13,000 individuals will die of this
disease [1]. Although survival for patients with localized disease is
high, patients with advanced disease face a poor prognosis despite
recently introduced targeted agents. Though loss of the von Hippel
Lindau (VHL) tumor suppressor gene is thought to be an initiating
event for the majority of RCCs [2], little is known about
subsequent genetic events and their respective impact on
tumorigenesis. Elucidation of these pathways will identify novel
therapeutic targets as well as facilitate biomarker development that
may have both diagnostic and prognostic significance.
Germline mutations of FH are associated with an inherited form
of renal cancer referred to as Hereditary Leiomyomatosis and
Renal Cell Cancer (HLRCC) [3,4]. FH encodes the tricarboxylic
acid cycle enzyme fumarate hydratase (also referred to as
fumarase) which catalyzes the hydration of fumarate to form
malate. Individuals with HLRCC are predisposed to the
development of leiomyomas of the skin and uterus in addition to
highly malignant and lethal RCC. The mechanisms of tumori-
genesis proposed have largely focused on the biochemical
consequences of loss of FH enzymatic activity. It has been
proposed that loss of FH leads to fumarate accumulation and
promotes a pseudohypoxic state in which hypoxia response
pathways are aberrantly activated despite normoxic conditions
[5]. Fumarate has been shown to inhibit proline hydroxylation of
the hypoxia inducible factors HIF-1a and HIF-2a which are
catalyzed by a family of enzymes referred to as the HIF prolyl
hydroxylases (PHDs) [5]. In their unhydroxylated form, HIFas
avoid recognition by the E3 ubiquitin ligase VHL (which targets
these proteins for proteosomal degradation) and are thus stabilized
[6,7,8,9]. Under these conditions either HIF-1a or HIF-2a are
able to heterodimerize with the constitutively expressed protein
HIF-1b, also referred to as ARNT (recently reviewed [10]). This
heterocomplex is able to transcriptionally activate several genes
including VEGF and other growth factors that may be pro-
tumorigenic when dysregulated. Pseudohypoxia has also been
implicated in the most common variant of RCC, clear cell
carcinoma (ccRCC), in which loss of VHL is a common genetic
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e21037event [11]. As expected, elevated levels of HIF-1a and/or HIF-2a
are noted in clear cell renal cancers [12,13]. Interestingly, several
lines of evidence indicate that HIF-2a as opposed to HIF-1a,i s
critical to RCC formation and/or progression [14,15,16].
While VHL loss is clearly critical to HIF-2a stabilization,
alternate mechanisms, besides the prevention of degradation,
may play a role in the maintenance of HIF-2a in renal cancer.
Previous work by Block et al. established a role for reactive oxygen
species (ROS) generated by NADPH oxidases in maintaining
HIF-2a protein expression through an AKT-dependent mRNA
translational mechanism in VHL-deficient cells [17]. In addition,
mTOR signaling complex 2 (mTORC2), a known activator of
AKT signaling, has been shown to promote HIF-2a accumula-
tion in VHL null renal carcinoma cells [18]. More recently,
treatment of RCC cells with a dual PI3K/mTOR inhibitor
suppressed the expression of HIF-2a [19]. These data support the
notion that ongoing HIF-2a synthesis is critical to the
maintenance of this oncogenic transcription factor in renal
cancer cells.
FH mutations have primarily been linked to papillary type II
renal cancer, a histologic variant that accounts for less than 10%
of all renal cancers [20]. FH mutations have not been identified
in sporadic clear cell renal cancer. However, a recent report has
linked FH to the development of clear cell renal cancer in a
patient with a germline mutation of FH [21]. To date, the
expression and function of FH in ccRCC has not examined.
Therefore, we investigated the role of FH in sporadic clear cell
renal cancer.
Results
Reduced expression of FH in clear cell renal carcinoma
FH expression in ccRCC has yet to be explored. Therefore, we
first examined the protein expression of FH in a panel of human
clear cell renal tumors and patient-matched normal renal
parenchyma. Immunoblot analysis of tissue lysates demonstrated
a marked reduction of FH protein levels in the tumors as
compared to normal adjacent tissue (Figure 1A). To confirm our
findings, we performed immunohistochemical staining for FH on
patient matched tumor/normal pairs. These results correlated
with our immunoblotting results in that staining for FH was less in
tumors relative to control renal tissue (Figure 1B). We next
examined FH protein levels in a panel of established ccRCC cell
lines (786-O, A498, RCC4, and ACHN). All cultured cell lines
demonstrated reduced FH protein levels relative to normal kidney
(Figure 1C). We then examined mRNA expression levels of FH in
tumor tissue as compared to patient-matched normal renal tissue
in specimens from the Cooperative Human Tissue Network (NCI).
Quantitative real time RT-PCR demonstrated reduced FH
mRNA levels in tumor tissue as compared with normal tissue
(Figure 2). Analysis of mRNA levels reveals that over 70% of the
tumor samples demonstrated reduced FH mRNA levels relative to
normal matched renal parenchyma. Moreover, 15/32 patient
samples (47%) demonstrated a greater than twofold reduction in
FH mRNA levels in tumor samples relative to normal control.
Overall, the average reduction in FH mRNA levels was 2.9 fold.
This difference was determined to be statistically significant. These
Figure 1. FH protein expression id reduced in clear cell renal cancer. A) Protein was isolated from clear cell (CC) tumor samples (T) in
addition to matched normal renal parenchyma (N). Proteins were immunoblotted for FH protein levels. GAPDH immunoblot is included as a loading
control. B) Immunohistochemical staining for FH was performed on patient-matched tumor/normal pairs. Images were obtained with a 406objective
lens. C) FH protein levels in RCC lines relative to normal kidney. Actin is included as a loading control.
doi:10.1371/journal.pone.0021037.g001
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protein levels in ccRCC.
FH modulates HIF-2a levels
High levels of fumarate in FH-deficient RCC play a role in
stabilizing HIF-2a protein expression through inhibition of proline
hydroxylase activity thereby preventing VHL recognition. Based
on these data, we hypothesized that loss of FH should have no
impact on HIF protein levels in VHL null cell lines. However, we
found that siRNA-mediated knockdown of FH resulted in a
further increase of HIF-2a protein levels in two ccRCC lines
which are VHL null (786-O and A498) (Figure 3A). In support of
these findings, transient overexpression of FLAG-tagged FH (FH-
FLAG) reduced HIF-2a levels in 786-O cells (Figure 3B).
Together, this suggests that FH modulates HIF-2a protein
expression in the absence of VHL.
To further elucidate the mechanism by which FH regulate HIF-
2a protein expression, we created stable cells lines overexpressing
FH-FLAG in VHL-deficient 786-O cells. We identified 3 clones
that stably expressed the FH-FLAG construct. All 3 clones
demonstrated reduced HIF-2a levels as compared with control
vector transfected cells (Figure 3C). We initially considered
whether the effects on HIF-2a were transcriptionally mediated,
however we did not detect reductions in HIF-2a mRNA levels
with FH overexpression (data not shown).
FH loss activates AKT signaling
Recent reports have implicated PI3K/AKT signaling in
maintaining HIF-2a protein expression in VHL null cells through
a translational mechanism [17,18,19,22]_ENREF_17. Based on
these reports, we examined AKT signaling with FH modulation.
We found that siRNA-mediated knockdown of FH in both 786-O
and A498 cells results in increased AKT phosphorylation on serine
473 of AKT (Figure 4A). Correspondingly, overexpression of FH
lowered phospho-AKT levels in 786-O cells (Figure 4B) indicating
that FH levels inversely correlate with AKT signaling. We next
Figure 2. FH mRNA expression is reduced in clear cell kidney cancer. mRNA levels of FH were determined in a separate set of tumor samples
relative to patient matched normal renal parenchyma with real time RT-PCR (p=0.004). Expression levels were normalized to 18 s rRNA levels prior to
comparative analysis.
doi:10.1371/journal.pone.0021037.g002
Figure 3. FH expression impacts HIF-2a levels. A) VHL null 786-O
and A498 cells were transected with siRNA to FH and scramble control
(siNC). Forty-eight hours following transfection, protein lysates were
analyzed by immunoblotting for the indicated proteins. B) 786-O cells
were transiently transfected with control vector (CV) and vector
containing FLAG tagged FH. Forty-eight hours following transfection,
protein lysates were analyzed by immunoblotting for the indicated
proteins. FLAG immunoblot indicates successful expression of the
transgene. C) (Left) 786-O cells were stably transfected with CV and FH-
FLAG. After selection in puromycin, single cell clones were harvested
and screened for FLAG expression. HIF-2a levels were measured in FH-
FLAG expressing clones relative to CV transfected cells. Densitometry of
the bands is quantitatively displayed on the right. Mean relative values
+/2 standard deviation were obtained with ImageJ software from
independent experiments.
doi:10.1371/journal.pone.0021037.g003
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protein expression. Consistent with our previous findings, FH
knockdown activated AKT signaling and increased HIF-2a levels
compared to scramble transfected cells (siNC) (Figure 4C).
However, cotreatment of transfected cells with the PI3K inhibitor
LY-294002 blocked the increase in HIF-2a associated with FH
knockdown (Figure 4C). Together, this suggests that FH maintains
HIF-2a protein expression through mechanisms dependent on
PI3K and AKT signaling.
FH expression mediates cell migration and invasion
The biological consequences of FH overexpression in RCC cells
were next examined. FH null tumors are highly invasive and often
metastatic tumors [20], and HIF-2a has previously been
implicated in this cellular process [23]. Therefore, we investigated
the role of FH in cellular migration and invasion in ccRCC. We
find that knockdown of HIF-2a with siRNA in 786-O RCC cells
diminished cellular motility as determined by wound healing assay
compared to scramble transfected cells (Figures 5A and 5B).
Quantification of these results are provided in Figure 5C. While
almost 80% of the wound gap was closed in control transfected
cells by 12 hours, 50% of the wound gap remained in HIF-2a
knockdown cells. Given these data, we examined wound healing in
FH overexpressing 786-O subclones as compared with control
vector transfected cells. Both FH overexpressing clones had
significantly reduced wound closure as compared with control
vector transfected cells, suggesting that loss of FH contributes to
migration in RCC (Figure 6A). In control vector transfected cells,
the wound width gap was almost completely closed by 10 hours.
In contrast, FH overexpressing cells closed the wound gap by only
half by 10 hours indicating reduced cellular migration was a result
of FH overexpression. These results are displayed graphically
(Figure 6B). To further corroborate these data, we examined
cellular migration utilizing a chamber assay with 10% fetal bovine
serum as the chemotractant. 786-O vector control cells were
significantly more migratory than FH overexpressing clones
(Figure 6C). Finally, overexpression of FH in RCC cells reduced
their invasive ability as determined by matrigel invasion assay
(Figure 6D). Taken together, these data demonstrate that loss of
FH expression enhances the migratory and invasive ability of
RCC cells.
Discussion
In this report, we demonstrate for the first time reduced FH
expression at the mRNA and protein levels in clear cell renal
carcinoma, the most common histological variant that accounts for
the majority of kidney cancers. These findings are significant as
previous studies did not identify FH mutations in RCC lines as
well as primary RCC specimens [24]. The mechanisms by which
mRNA levels of FH are reduced are under current investigation.
Hypermethylation may be one mechanism by which FH
expression is suppressed. Dulaimi et al. did not identify
hypermethylation in a CpG island of the FH promoter in a panel
of papillary RCCs [25]. However, no studies to date have
examined FH methylation status in ccRCC. While hypermethyla-
tion is a means of tumor suppressor gene silencing, alternate
mechanisms may also account for the reduced expression of FH
we have identified. Recent interest has focused on the role of
Figure 4. FH expression impacts AKT signaling. A) VHL null 786-O and A498 cells were transfected with siRNA to FH and scramble control
(siNC). Forty-eight hours following transfection, protein lysates were analyzed by immunoblotting for total AKT and ser473 phospho-AKT. B) 786-O
cells were transiently transfected with control vector (CV) and vector containing FLAG tagged FH. Forty-eight hours following transfection, protein
lysates were analyzed by immunoblotting for the indicated proteins. C) 786-O cells were transfected with the indicated siRNA. Twenty-four hours
following transfection, media of the cells was replaced with media containing PI3K inhibitor LY-294002 (6.25 mM). Cells were then harvested 24 hours
later and protein lysates were subjected to immunoblot analysis for the indicated proteins.
doi:10.1371/journal.pone.0021037.g004
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that genes involved in oxidative phosphorylation may be subject to
regulation by miRNAs [26]. Clearly, these possibilities warrant
further investigation given the biological significance of our
findings.
We have previously demonstrated that reintroduction of wild
type FH into a FH deficient tumor cell line results in a marked
reduction in nuclear HIF-1a levels [27]. Moreover, siRNA
mediated knockdown of FH has been shown to increase HIF-1a
levels in A549 lung carcinoma cells which express VHL [5]. The
findings from these studies, as well as other biochemical studies,
suggest that the principle mechanism by which this occurs is
through HIF protein stabilization via inhibition of prolyl
hydroxylase activity as a result of FH loss. These findings would
therefore presume that the effect of FH on HIF would only be
evident in the presence of VHL. However, our findings are quite
novel in that they indicate that FH can modulate HIF-2a
independently of VHL. VHL-independent pathways that mediate
HIF degradation have been reported. In particular, Hsp90 and
RACK1 have previously been shown to modulate HIF-1a
degradation [28]. Therefore, it is possible that a similar
mechanism mediates HIF-2a degradation as well. Despite
stabilization via inhibition of protein degradation, there is growing
evidence that alternate pathways play a role in maintaining HIF-
2a protein levels in the absence of VHL. Block et al. demonstrated
that elevated cellular reactive oxygen species, mediated by p22-
phox based Nox oxidases, maintain HIF-2a protein levels in RCC
cells through an AKT/4E-BP1 mRNA translational dependent
mechanism [17,22]. Correspondingly, phosphorylation of AKT
and 4E-BP1 are enhanced in human RCC tissue relative to
normal parenchymal tissue [22]. More recently, Toschi et al. found
that AKT activation, via signaling through the mTOR signaling
complex 2 (mTORC2), was required to maintain HIF-2a in VHL
null cells [18]. AKT activation is a common signaling node in
cancer and alternate mechanisms may lead to AKT activation in
RCC including loss of FH.
The mechanism by which AKT signaling is activated by FH loss
is under current investigation. We have previously demonstrated
that loss of FH in renal epithelial cells results in elevated cellular
oxidative stress [27]. Hence, ROS may be a contributor to the
Figure 5. HIF-2a promotes migration in RCC cells. 786-O RCC cells were transfected with scramble control siRNA (siNC) or siRNA to HIF-2a.
Western blotting results of whole cell extracts are demonstrated in panel A. B) Wound healing assay was performed in transfected cells. Images were
serially taken at the indicated time point following ‘‘wound’’ induction. Results are graphically displayed in panel C. Asterisks (*) indicate statistical
significance with p,0.05 relative to scramble control transfected cells.
doi:10.1371/journal.pone.0021037.g005
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effects of FH loss may be unrelated to its role in the TCA cycle. It
is well established that FH also exists in an extramitochondrial,
cytosolic form. At this time, very little is known about the function
of this form of FH. However, recent evidence provided by
O’Flaherty et al. indicates that loss of extramitochondrial FH may
contribute to HIF stabilization [29]. In addition, cytosolic FH has
been implicated in the DNA damage response [30]. Upon DNA
damage, cytosolic FH has been shown to translocate into the
nucleus. The mechanism by which FH participates in the DNA
damage response remains unclear. However, there is certainly the
possibility that FH and the metabolites it interacts with may
regulate the function of other proteins, potentially within the
nucleus. Interestingly, AKT has also been shown to function in the
nucleus [31]. Given our data, as well as these recent reports,
targeting AKT mediated signaling pathways, either at the level of
AKT or upstream, may prove to be of therapeutic benefit for renal
cancer. This is in concordance with recent data demonstrating the
in vitro and in vivo efficacy of a dual PI3K/mTOR inhibitor in RCC
[19].
Interestingly, there is precedent for alterations of TCA cycle
enzyme in cancer. Multiple other genes encoding enzymes of the
tricarboxylic (TCA) cycle are considered tumor suppressor genes
including SDHB, SDHC, and SDHD (Succinate Dehydrogenase
subunits B,C,D) [32,33,34]. SDH subunit mutations have been
linked to pheochromocytoma and paraganglioma and more
recently to gastrointestinal stromal tumor (GIST) [35]. In addition
to mutations, alterations of expression of these genes have been
linked to malignancy. Dahia et al. demonstrated reduced
expression of succinate dehydrogenase subunit B (SDHB) in a
subset of pheochromocytomas [36]. More recently, reduced
expression of SDHB was identified in large proportion of GISTs
without mutations in SDHB or other genes commonly mutated in
GISTs including KIT and PDGFRA [35]. Based on these data, a
potential unifying theme may be that defects in oxidative
phosphorylation, either through mutation or expression changes,
have a role in oncogenesis. Recently, Chen et al. proposed that
oxygen consumption via mitochondrial metabolism may regulate
tumor growth by limiting the availability of oxygen for non-
mitochondrial activities that are contributory to tumor growth
[37].
Of significant interest is our finding that FH overexpression
results in reduced migration and invasion of RCC cells. Our data
are in concordance with a recent report by Costa et al. that
demonstrated that fh knockdown in immortalized mouse embry-
onic fibroblasts (iMEFS) resulted in increased motility as compared
with untransduced iMEFS [38]. Moreover, the increase in motility
was HIF-1a dependent. The role of HIF-2a in their studies could
not be determined as they were unable to detect HIF-2a
expression in fh deficient iMEFS. Our studies focused on HIF-
2a given prior studies that implicate its role in renal carcinogen-
esis. Given that HIF-2a knockdown in RCC cells inhibits
migration, our data indicate that the effects of FH overexpression
on migration and invasion are, in part, mediated by effects on
HIF-2a. HIF-2a has previously been implicated in the invasive
behavior of RCC cells. Moreover the invasive promoting
properties of HIF-2a have been studied in 786-O cells, the same
cells utilized in this study. Hughes et al. demonstrated that HIF-2a
knockdown in 786-O cells reduced the expression of multiple
integrins that may mediate cell motility and invasion [39]. Petrella
et al. examined the role of VHL loss in cell invasion [40]. They
found that reintroduction of wild type VHL into VHL-deficient
786-O cells reduced HIF-2a levels and cell invasion. Conversely,
re-expression of HIF-2a in VHL reconstituted 786-O cells restored
invasive potential. These data indicate a role for HIF-2a in RCC
migration and invasion. Additionally, HIF-2a overexpression was
found to enhance the growth of RCC xenografts whereas
overexpression of HIF-1a was found to inhibit xenograft growth
[41]. Correspondingly, separate studies indicate that HIF-2a, but
not HIF-1a, contributes to the growth of VHL null tumor
xenografts [16,42]. Hence, our data add to the growing body of
evidence demonstrating the tumor-promoting effects of HIF-2a
expression in RCC.
Despite the recent approval of multiple agents for advanced
renal cancer, most patients with advanced renal cancer will
eventually succumb to their disease. Hence, the identification of
novel signaling pathways will be critical to the development of
effective therapeutics. There is now mounting evidence that renal
cancer is among the tumors that are representative of the
emerging paradigm in cancer biology of metabolic links to
malignancy. Our findings with FH suggest a metabolic repro-
gramming in clear cell renal cancer that promotes expression of
tumorigenic factors including HIF-2a via multiple mechanisms.
Unraveling the mechanisms by which tumor metabolism is altered
and the downstream cellular consequences should provide deep




A498, 786-O, and ACHN cells were obtained from the
American Type Culture Collection and maintained in DMEM
supplemented with 10% heat-inactivated fetal bovine serum at
37uC in a humidified 5% CO2 atmosphere. RCC4 cells were
kindly provided by P. Ratcliffe (Oxford).
Chemicals
LY294002 was purchased from Sigma.
Constructs
The FH-FLAG construct has been previously described [27].
Immunoblotting
All immunoblot analyses were performed as previously
described [27] on whole-cell lysates prepared with the use of
radioimmunoprecipitation assay buffer (50 mM Tris-HCl,
150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate,
and 0.1% sodium dodecyl sulfate) supplemented with protease
inhibitor cocktail (Roche). Antibodies were obtained from the
following commercial sources: GeneTex (FH-immunoblotting),
Santa Cruz Biotechnology (FH-immunohistochemistry), Novus
(GAPDH, HIF-2a), Sigma (Tubulin, b-Actin), Cell Signaling (total
AKT and ser473 phospho AKT).
Figure 6. Migration and Invasion assays in 786-O cells transfected with control vector (CV) or FH-FLAG. A) Wound healing assay images
at the indicated time points. B) Wound width distance at the indicated time points. C) Chamber cell migration assay of the indicated clones. Cells
were seeded in serum free media with 10% FBS used as the chemotractant. Migrated cell counts of clones at 48 hours from initial seeding. Asterisks
(*) indicate statistical significance with p,0.05 relative to control vector transfected cells. D) Matrigel invasion assay with 10% FBS media as the
chemotractant. Asterisks (*) indicate statistical significance with p,0.05 relative to control vector transfected cells.
doi:10.1371/journal.pone.0021037.g006
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Biospecimens for RNA analysis were obtained from the
Cooperative Human Tissue Network of the NCI/NIH. Total
RNA was reverse transcribed using the High-Capacity cDNA
Archive kit (Applied Biosystems). cDNA was then used as template
with Applied Biosystems’ assays-on-demand 206 assay mix of
primers and Taqman probes. Forty amplification cycles were done
on the Applied Biosystems Prism 7900 sequence detector. Fold
change values between tumor and normal samples were calculated
using the DCt method with normalization to 18S rRNA levels. As a
statistical test we used the Mann-Whitney paired non-parametric
test to compare FH expression in tumor versus normal adjacent
tissue (implemented in GeneSpring, Agilent).
Immunoblotting and immunohistochemistry of human
tumor specimens
Tumor samples and normal corresponding tissue from patients
with RCC were obtained from the Department of Urology at the
University of Texas Health Science Center at San Antonio. The
tumors for this study were histologically classified as clear cell renal
carcinoma by a genitourinary pathologist. The collection and
handling of human samples was performed according to a protocol
approved by the Institutional Review Board of the University of
Texas Health Science Center at San Antonio. Based on the
protocol, samples were obtained in a deidentified fashion from
patients undergoing surgical resection for renal cancer. As samples
were obtained and analyzed in an anonymous fashion, patient
consent was not required.
Wound healing assay
Cells were allowed to grow to near confluence in 60 mm dishes.
A uniform scratch was then made down the center of the plate
using a 200 microliter micropipette tip, followed by washing twice
with PBS. The same marked field of the scratch wound was
photographed using an Olympus light microscope (46 objective)
at the indicated time points. The width of the scratch wound was
measured at three different areas with Q-Capture pro software.
Quantified data represent the mean +/2 S.D. from at least two
independent experiments.
Migration assay
786-O subclones cells (1610
4) were seeded on an 8 mM pore
size Thin-cert for 24 well plates (Greiner Bio-One) in serum free
media. Seven hundred fifty microliters of 10% FBS medium was
added to the bottom chamber as chemotractant. After 48 hrs, cells
on the top of the membrane were removed with a cotton swab.
The migrated cells at the bottom side were washed with PBS, fixed
with 70% ethanol and stained using 0.1% Crystal violet to
visualize the migrated cells. Migrated cells attached to the lower
side of the membrane were enumerated using a light microscope
at 106magnification. Counts represent the average cell number of
ten microscopic fields.
Invasion assay
Cell invasion was determined by invasion assay (membrane
coated with a layer of Matrigel extracellular matrix proteins)
according to the manufacturer’s instructions. Cells were seeded in
serum-free medium into the upper chamber and invaded toward
the bottom chamber containing a 10% FBS medium as the
chemotractant. Membranes were processed in a similar fashion as
the migration assay.
RNA interference
For FH and HIF-2a knockdown, cells were transfected with
pooled siRNA reagent (Thermo Fisher) with the Amaxa
Nucleofector system according to the manufacturer’s protocol.
Cells were harvested at 48–72 hours following transfection. A non-
targeting scramble siRNA pool was used as a negative control
(Thermo Fisher).
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